Describing deprescribing trials better: an elaboration of the CONSORT statement by Blom, J W et al.
Bond University
Research Repository
Describing deprescribing trials better: an elaboration of the CONSORT statement
Blom, J W; Muth, C; Glasziou, P; McCormack, J; Perera, R; Poortvliet, R K E; Numans, M E;
Thürmann, P; Thiem, U; Thio, S L; Van Driel, M; Beyer, M; Van den Akker, M; Knottnerus, J A
Published in:
Journal of Clinical Epidemiology
DOI:
10.1016/j.jclinepi.2020.07.011
E-pub ahead of print: 01/11/2020
Document Version:
Publisher's PDF, also known as Version of record
Link to publication in Bond University research repository.
Recommended citation(APA):
Blom, J. W., Muth, C., Glasziou, P., McCormack, J., Perera, R., Poortvliet, R. K. E., Numans, M. E., Thürmann,
P., Thiem, U., Thio, S. L., Van Driel, M., Beyer, M., Van den Akker, M., & Knottnerus, J. A. (2020). Describing
deprescribing trials better: an elaboration of the CONSORT statement. Journal of Clinical Epidemiology, 127, 87-
95. https://doi.org/10.1016/j.jclinepi.2020.07.011
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
For more information, or if you believe that this document breaches copyright, please contact the Bond University research repository
coordinator.
Download date: 11 Sep 2020
Journal of Clinical Epidemiology 127 (2020) 87e95ORIGINAL ARTICLE
Describing deprescribing trials better: an elaboration of the CONSORT
statement
Jeanet W. Bloma,*, Christiane Muthb, Paul Glasziouc, James P. McCormackd, Rafael Pererae,
Rosalinde.K.E. Poortvlieta, Mattijs E. Numansa, Petra Th€urmannf, Ulrich Thiemg,h,
Sioe Lie Thioa, Mieke Van Drieli, Martin Beyerb, Marjan Van den Akkerb,j, J. Andre Knottnerusj
aPublic Health and Primary Care, Leiden University Medical Center, Leiden, The Netherlands
bInstitute of General Practice, Goethe University Frankfurt/Main, Frankfurt am Main, Germany
cInstitute for Evidence-Based Healthcare, Faculty of Health Sciences & Medicine, Bond University, Gold Coast, Australia
dFaculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, Canada
eNuffield Department of Primary Care Health Sciences, Medical Statistics, University of Oxford, Oxford, UK
fDepartment of Clinical Pharmacology, University of Witten/Herdecke, Helios University Hospital Wuppertal, Witten, Germany
gCentre of Geriatrics and Gerontology, Albertinen-Haus, Hamburg, Germany
hGeriatrics and Gerontology, University Medical Centre Eppendorf, Hamburg, Germany
iFaculty of Medicine, Primary Care Clinical Unit, The University of Queensland, Brisbane, Australia
jDepartment of General Practice, Care and Public Health Research Institute, Maastricht University, Maastricht, The Netherlands
Accepted 9 July 2020; Published online 22 July 2020AbstractObjective: The objective of this study was to identify key features to be addressed in the reporting of deprescribing trials and to elab-
orate and explain CONSORT items in this regard.
Study Design and Setting: As a first step in a multistage process and based on a systematic review of deprescribing trials, we elab-
orated variation in design, intervention, and reporting of the included trials of the review. We identified items that were missed or insuf-
ficiently described, using the CONSORT and TIDieR checklists. The resulting list of items, which we considered relevant to be reported in
deprescribing trials, were discussed in a single-round Delphi exercise and subsequently in a full-day face-to-face meeting with an interna-
tional panel of 14 experts. We agreed on CONSORT items for further elaboration with regard to design and reporting of deprescribing trials.
Results: We identified seven CONSORT items on trial design, participants, intervention, outcomes, flowchart, and harms, where the in-
vestigators of deprescribing trials should take into consideration specific aspects, such as whether or not to use placebo or how to inform
participants.
Conclusion: This article presents an elaboration to the CONSORT statement for the reporting of deprescribing trials. It may also sup-
port investigators in motivated design choices.  2020 The Authors. Published by Elsevier Inc. This is an open access article under the CC
BY license (http://creativecommons.org/licenses/by/4.0/).Keywords: Deprescribing; Reporting guidelines; CONSORT statement; Study design; Primary care; Randomized controlled trial1. Introduction
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4.0/).medication overload [1]. In older patients, the prevalence of
polypharmacy, mostly defined as five or more medications
[2], is approximately 30e40% across Europe [3]. This poses
an extra challenge to clinical care, as older people with poly-
pharmacy are more often prone to adverse drug reactions [4]
and poor adherence [5]. Potential risksmay outweigh the ben-
efits [6e8].However, deprescribing is also a key issue in tack-
ling problems of overuse andmisuse in younger patients, such
as is the case for opioids [9] and benzodiazepines [10].
We define deprescribing as ‘‘the process of withdrawal
of medication, supervised by a health care professional’’
which is partly based on the definition proposed by Reeves article under the CC BY license (http://creativecommons.org/licenses/by/
ical Epidemiology 127 (2020) 87e95What is new?
Key findings
 All CONSORT-items are applicable to deprescrib-
ing trials but certain items need more elaboration:
trial design, participants, intervention, outcomes
and harms, and the flowchart.
What this adds to what was known?
 The article presents an elaboration/explanation of
the CONSORT statement with regard to specific
considerations in deprescribing trials, addressing
both single and multiple medication deprescribing.
 The proposed framework supports the reporting of
a deprescribing trial, but also the planning of its
design and measurements of fidelity and outcomes
to capture the entire deprescribing process.
What is the implication and what should change
now?
 Deprescribing trials require specific design and
outcome measurement issues to be carefully
considered and described.
 As appropriate medication advice increasingly in-
volves deprescribing, registration authorities and
public supervision should stipulate well designed
and reported deprescribing studies as a criterion
for medication registration.
et al. previously. [11] Not only can deprescribing aim to
improve outcomes but it also includes discontinuation of
medication that is unnecessary or was initially prescribed
for good reasons, but can later become inappropriatedfor
example, when there is no longer an indication for it, or
when harms outweigh the benefits [11,12]. Moreover, this
definition takes into consideration that deprescribing is a
process rather than just the act of stopping a drug, which
may include decision making in prioritization when simpli-
fying regimens, avoiding harms when tapering dosages, and
taking into account patient preferences. Furthermore, the
process of deprescribing is closely intertwined with atti-
tudes and behaviors of clinicians and patients [13,14].
To address these challenges, an increasing number of de-
prescribing trials has been conducted, often evaluatingmulti-
facetted (i.e., complex) interventions to reduce medication
overload [15e18]. Deprescribing trials need to report all
relevant information to support the clinician in replicating
the process in their practice and to allow estimating the inter-
nal and external validity of the results. Among the many re-
porting guidelines [19], the CONSORT statement for the
reporting of randomized controlled trials and the TIDieR
statement for the adequate reporting of (complex)
88 J.W. Blom et al. / Journal of Clininterventions are most applicable for deprescribing trials
[20,21]. A recent systematic review of deprescribing trials
concluded that the quality of reporting needs to be improved,
as deprescribing trials failed to adequately report important
characteristics, such as patient selection and recruitment,
choice of control condition, and length of follow-up [22,23].
We aimed first to contribute to improving the specific re-
porting of deprescribing trials, addressing both single and
multiple medication deprescribing, and second to support-
ing the design of a trial and its measurements of fidelity
and outcomes capturing the entire deprescribing process.
We elaborated and explained deprescribing trial-relevant
items of the CONSORT statement to an international group
of experts also taking into account the TIDieR statement.2. Methods
Using the results of a systematic review of deprescribing
trials, which included studies evaluating the discontinuation
or tapering of single ormultiplemedications [22], we set up a
multistage process to develop a reporting guide on depres-
cribing trials. First, we (J.W.B., S.L.T.) assessed the RCTs
included in the aforementioned review to explore the varia-
tion in design, intervention, and reporting, using the CON-
SORT and TIDieR checklists [20,21]. From this process,
we identified items that were missed or insufficiently
described. Subsequently, we (J.W.B., S.L.T.) made a list of
items considered relevant to be reported in deprescribing tri-
als. Second, in a single-round Delphi exercise, this list was
sent to an international panel of 14 experts on pharmacology
(J.Mc.C., P.T.), geriatric medicine (U.T.), general practice
and clinical epidemiology (J.W.B., P.G., S.L.T., C.M.,
M.V.D.A., M.V.D., M.B., M.E.N., J.A.K., R.K.E.P.), statis-
tics (R.P.), and reporting quality guidelines (P.G.) to be com-
plemented with suggestions based on their expertise.
Third, the results from the Delphi process were presented
and discussed in a full-day face-to-face meeting with the
expert panel to agree upon on CONSORT items to be elabo-
rated and explained with regard to specific considerations in
deprescribing trials. The TIDieR statement on the appropriate
reporting of interventions was also taken into consideration to
avoid redundancies to existing universal reporting guidelines.
Subsequent to the meeting, we elaborated and explained the
CONSORT items with regard to design and reporting of de-
prescribing trials considering selected examples to illustrate
the items under consideration. The multistage process was
prepared by the first and last author and led by the first author.3. Results
In the included trials of the systematic review [22], we
identified the following omissions in outcome reportingd
either as missed information or as incomplete reporting:
relapse of symptoms, restart of medication and the
89J.W. Blom et al. / Journal of Clinical Epidemiology 127 (2020) 87e95incidence of adverse events. In the Delphi process, the
following issues were raised for elaboration: recruitment
and selection of study participants, relevant details of the
deprescribing intervention, adequate selection of the con-
trol condition, and specific considerations on sample size
and harms. During the meeting, we determined the report-
ing of deprescribing trials following the CONSORT state-
ment and the TIDieR statement would suffice. We
identified no new issues that had not been covered by both
statements in general. However, we identified the need for
further explanation of the following CONSORT items with
regard to deprescribing (see also supplemental table):





14: Follow up (14a).
19: Harms.Example 2
The DART-AD trial aimed to assess whether
continued treatment with antipsychotics in people
with Alzheimer’s disease is associated with an
increased risk of mortality. The intervention group
received a placebo [26].3.1. CONSORT item 3adtrial design
3.1.1. 3a: Description of trial design (such as parallel,
factorial) including allocation ratio
We considered the following subjects important with re-
gard to study design of a deprescribing trial: Placebo medi-
cation or no medication in the intervention group,
noninferiority design, and the unit of randomization.
3.1.1.1. Placebo medication or no medication in interven-
tion group. It is common and sometimes required to use pla-
cebo or sham interventions as a comparator in randomized
controlled trials to control for the placebo and nocebo effect
to detect beneficial effects as well as the adverse effects of
the actual treatment [24,25]. In deprescribing trials, the use
of placebo medication is less straightforward because de-
prescribing usually includes discontinuation of the visible
act of being prescribed medication (example 1) [23]. FromExample 1
In a trial to determine the effect of withdrawing
diuretic medications on edema in patients who were
prescribed diuretics for ankle edema, participants
continuing their diuretics were compared with those
who stopped using them. The outcome was the pres-
ence of edema at several time intervals. In this trial,
no placebo was used because the researchers were
interested in the overall effect of withdrawing di-
uretics compared with continuation of the treatment,
as this is the intervention that would actually take
place in practice. Moreover, in this scenario it would
be tricky to use a placebo because of the many
different types and combinations of diuretics in prac-
tice [8].a methodological perspective, we should consider that
placebo-controlled deprescribing, where the active interven-
tion to be tested is in fact deprescribing, would require ‘‘pla-
cebo deprescribing’’ as a control condition [23]. This would
then control for the visible act of deprescribing while in fact
the pharmacological intervention is continued, and would
need a highly sophisticated design in which the administra-
tion of medication is masked, for example, via other, not de-
prescribed medication, or food. To our knowledge, such a
design has never been used, perhaps because of its obvious
complexity.
When the aim of the trial is to study the specific pharma-
cological effect of deprescribing, then placebo-controlled
deprescribing in accordance with one of two design options
would be advisable: first, the aforementioned comparison
with placebo deprescribing, and second, by comparing a
deprescribing group receiving placebo with a control group
continuing to use the medication (example 2). In the latter
option, however, the practically important element of
ending the visible act of taking pills is not part of the
evaluation.
In deprescribing trials, it should be explicitly reported
whether or not a placebo has been used, including a justifi-
cation and explanation what placebo entails in which of the
compared groups.3.1.1.2. When noninferiority trials may be applicable. De-
prescribing trials may assess effectiveness addressing two
kinds of outcomes:
1. A noninferiority or equivalence outcome implies that
the patient is not worse off after stopping the medica-
tion. For instance, their quality of life or functioning
or the manifestation of symptoms is not worse than
when they were taking the medication. Therefore,
from a clinical perspective, it is often not necessary
to demonstrate that discontinuing is better, as not tak-
ing the medication reduces their risk of medication
related harm and reduces cost. Accordingly, a depres-
cribing trial design can work with one-sided testing
[27]. See also the CONSORT extension on reporting
of noninferiority and equivalence trials (example 3)
[28].
2. A superiority outcome implies that deprescribing
would lead to an improvement of the patient’s well-
Example 3
The benefit of discontinuing statin therapy in the
setting of advanced, life-limiting illness is tested in
a clinical trial set in palliative care. It is known that
prescribing statins for primary or secondary preven-
tion for people with a life expectancy of many years
is beneficial, but the participants of this study had a
limited life expectancy. The trial aimed to study if
discontinuing was not clinically inferior to continuing
medication and therefore used a noninferiority design
[29].
90 J.W. Blom et al. / Journal of Clinical Ebeing, for instance, owing to a lower risk of adverse
drug reactions. Superiority of deprescribing a single
medication compared with continuation can also be
shown in a noninferiority trial if the positive effect
of deprescribing is obvious, or if the study shows non-
inferiority on the primary outcome but superiority on
other outcomes [30].Example 5
The statin deprescribing trial for palliative care pa-
tients was based on the hypothesis that the adverse ef-
fects of continuing statin use would outweigh the3.1.1.3. Unit of randomization. Prescriber barriers/en-
ablers to deprescribing have been described and are related
to problem awareness; inertia, that is, the failure to act;
self-efficacy; and feasibility of altering prescribing given
external constraints [25]. Clinicians need to change their
attitude toward deprescribing to overcome these barriers.
When it is likely that the clinicians’ attitude can influence
the outcomes, that is, there is a high risk of the clinician
giving the control group similar treatment (contamination),
a cluster-randomized design may be preferred with the
clinician or practice as the unit of randomization
(example 4) [20,24].Example 4
The ECSTATIC trial (Evaluating Cessation Statins
and Antihypertensive Treatment in primary Care) is a
cluster-randomized controlled trial designed to deter-
mine whether deprescribing preventive cardiovascu-
lar medication in patients without a strict indication
for such medication in accordance with current
guidelines is safe and cost-effective in comparison
with usual care in general practice. A cluster-
randomized design was used in which randomization
at general practice level was performed. As partici-
pants were receiving the intervention from their gen-
eral practitioner, the uptake of the intervention can be
influenced by the general practitioner’s way of work-
ing. In this case, a cluster-randomized design is use-
ful [30].3.2. CONSORT item 4dparticipants
3.2.1. 4a: Eligibility criteria for participants
3.2.1.1. Selecting and inviting participants. Deprescribing
trials can address clinical questions such as the cessation of
inappropriate medication, or societal questions like a reduc-
tion of cost-ineffective treatments, or questions with a focus
on the patient’s perspective, such as the reduction of treat-
ment burden or adverse effects. The trial’s objective has
consequences for the methods used for case finding and pa-
tient recruitment. For example, when a reduction of adverse
effects is the focus, patients will be invited to participate in
the trial when the adverse effect is detected. In trials target-
ing specific drugs a systematic case finding method based
on electronic medical records notes may be applicable [30].
However, apart from the trial’s objectives, other reasons
may impact the selection of participants. The patient’s (un)
willingness to attempt deprescribing has been reported to
be prone to similar enablers and barriers as in prescribers
[13], as well as the prescriber’s perception of the patient’s
willingness to accept and maintain deprescribing [14]. In
addition, the way patients are involved in the decision pro-
cess about deprescribing plays a large role in a patient’ de-
cision to participate (example 5) [31,32].
Important for clinicians reading the study report is infor-
mation about how patients were selected and included in
the trial, to gain an unbiased idea about the intervention ef-
fect and its applicability to an individual patient.
pidemiology 127 (2020) 87e95beneficial effects. Incorporating patient preferences
in the decision to discontinue was seen as a key
element as there was no clear superior option with
clinical benefit. However, the fact that patients who
were not willing to discontinue medication were not
included in the trial, could be seen as selection bias
[29].3.2.1.2. Information supplied to the participants. Depres-
cribing implies that patients have to stop taking a treatment
they are used to or for which they may even have developed
pharmacological dependency [31]. The idea of deprescrib-
ing thus may cause resistance in prescribers as well as pa-
tients. For patients, the deprescribing authority (medical
specialist, clinical pharmacist) might strongly influence
the willingness to stop medication [33]. Furthermore, pa-
tients (dis)agreement with ‘‘appropriateness’’ of cessation,
absence/presence of a ‘‘process’’ for cessation (such as time
to discuss with the physician), and negative/positive
91J.W. Blom et al. / Journal of Clinical Epidemiology 127 (2020) 87e95‘‘influences’’ to cease medication (such as opinions of fam-
ily or previous experiences with cessation), and ‘‘fear’’ of
cessation and ‘‘dislike’’ of medication play an important
role [14,31]. It is therefore important to report how and
by whom various arguments are presented and discussed
and what safety netting is offered.3.3. CONSORT item 5dintervention
3.3.1. 5: The interventions for each group with sufficient
details to allow replication, including how and when
they were actually administered
In deprescribing trials, interventions can be either simple
or complex. They are usually developed based on a theory or
previously established evidence and may be inspired by cli-
nicians wanting to deprescribe a drug due to a lack of added
value, by pharmacists [34] or by health insurance providers.
As deprescribing is associated with attitudes and behavior
and deprescribing interventions often imply behavior
changes, describing the incentives and barriers within a trial
is important to inform future implementation. This can be
done by following the TIDieR checklist. This description
will include the approach/framework used to establish
behavioral change of the patient, the prescriber or other
health professionals involved. Of particular importance is
the setting: during a routine office visit, during hospital stay,
and which caregivers and/or relatives are involved. Some-
times patients seek advice from other care providers about
their medication. Therefore, collaboration with other care
providers is important to keep track of the medication the pa-
tient is using or not using. Deprescribing could lead to
withdrawal-related effects, which also requires a construc-
tive collaboration between hospital physicians and primary
care to monitor patients after deprescribing [35].
The schedule of the discontinuation process, that is, time
frame of tapering and the dosage-scheme, the time frame of
monitoring and the items to monitor, should be included.
Because this process is far more complex than simply start-
ing a new medication, a clear description of the process
should be provided. The protocol should describe criteria
for when and how to restart the medication (example 6).Example 6
The ECSTATIC trial added an appendix to the
article including the schedule of the discontinuation
process of antihypertensive and lipid-lowering medi-
cation, the time frame for monitoring and the items to
monitor, that is, which symptoms to ask for. In addi-
tion, the health professionals involved were
mentioned. In a workshop at the start of the study,
all health professionals were informed about the
study [30].Apart from the intervention, clear information about the
usual care option should be provided. In a cluster-
randomized trial, primary care physicians in the control
group may receive some sort of intervention, too, for
example, a lecture about multimorbidity and polypharmacy,
but without special training for deprescribing, the materials
and further support. Deprescribing may also be part of
usual care. It is therefore necessary to document medication
changes in the control group as well.
3.4. CONSORT items 6, 19 and 14adoutcomes, harms
and follow up time
3.4.1. Outcomes
3.4.1.1. 6a: Completely define prespecified primary and sec-
ondary outcomemeasures, including howandwhen theywere
assessed (andwhat length of follow-upwas chosen); with rea-
sons. The improvement/equivalence of outcomes is related
to the reduction/equivalence of harmful effects of medica-
tions and may cover a full range of potential outcomes, such
as the reduction/equivalence of hospitalization and mortal-
ity, the improvement/equivalence of quality of life, physical
and cognitive functioning, and the prevention of falls. De-
prescribing may also contribute to a patient’s satisfaction
about the medication regimen and treatment burden. How-
ever, the attribution of deprescribing effects on clinical
and patient-relevant outcomes may sometimes be difficult,
in particular in older patients with multiple conditions and
medications. Therefore, process measures are often chosen
such as the withdrawal or dose reduction of particular med-
ications (example 7) [36], the reduction in high-risk pre-
scribing indicators [35], or the reduction of the total
number of medications [36]. Moreover, the assessment
and detailed description of fidelity may be necessary to
address the nature of deprescribing as a multilevel process.
Figure 1 provides an overview on different levels of fidelity
and outcome issues in deprescribing. Although not all levels
will apply to every deprescribing trial, a systematic
approach should guide the planning process on what to mea-
sure as well as the reporting.Example 7
Outcomes in a randomized trial in family practice
on withdrawal from long-term benzodiazepine use
were reported as ‘‘success, no use or no more than
once every 15 days; reduced, at least a 50% reduction
in initial dose; failure, no change or a decrease small-
er than 50%’’ [36].3.4.2. Harms
3.4.2.1. 19: All-important harms or unintended effects in
each group. Adverse drug reactions (ADRs) are defined
as an ‘‘appreciably harmful or unpleasant reaction, result-
ing from an intervention related to the use of a medicinal
Fig. 1. Multilevel measurement issues of fidelity and outcomes in deprescribing. PROMs, patient-reported outcome measures; PREMs, patient-
reported experience measures.
92 J.W. Blom et al. / Journal of Clinical Epidemiology 127 (2020) 87e95product, which predicts hazard from future administration
and warrants prevention or specific treatment, or alteration
of the dosage regimen, or withdrawal of the product’’ [37].
ADRs may mediate the outcome in a medication trial as
well as in deprescribing trials where adverse drug with-
drawal reactions (ADWRs) may arise (Fig. 2). ADWRs
are usually subsumed to ADRs [38] and may occur in
different forms: (i) true physiological withdrawal reactions,
such as gastric complaints as a rebound phenomenon after
stopping a proton pump inhibitor [39], or (ii) onset of new
symptoms after the discontinuation of benzodiazepines and
opioids [36] (example 8), and (iii) symptom relapse, such
as worsening edema after withdrawing diuretic therapyIntervenƟon Reduced MedicaƟons 
Fig. 2. Outcomes in defor heart failure [8]. These forms have different conse-
quences in clinical management. Although ADWRs of i
and ii gradually fade over time and are often preventable
by means of appropriate strategies such as slowly tapering
dosages or temporarily prescribing comedication, a (iii)
symptom relapse with a subsequent restart of the medica-
tion indicates the failure of deprescribing. The reporting
of all-important harms or unintended effects in each of
the intervention and control group should therefore also
include the form of ADWR when possible. Sometimes, this
may be difficult,for example, as in the reporting of ADWRs
in the discontinuation of serotonin-noradrenalin reuptake






‘‘An adverse event will be defined as any unfavor-
able or unintended sign, symptom, or disease that
could reasonably be associated with discontinuation
of BZD [benzodiazepines]. These include tremor,
anxiety, insomnia, convulsions, irritability, and dizzi-
ness. Physicians will report any withdrawal symptom
related to BZD discontinuation to the trial coordi-
nating center, and the data will be analyzed by a
safety committee’’ [36].
93J.W. Blom et al. / Journal of Clinical Epidemiology 127 (2020) 87e95multiplicity of symptoms, which may be easily misidenti-
fied as signs of relapse [40].
3.4.3. Follow-up time
3.4.3.1. 4a: Dates defining the periods of recruitment and
follow up.
In a medication trial, the length of follow-up is decided
by the expected time to effect. However, in a deprescribing
trial one has to have an expectation about when not to
expect an effect of withdrawal any more. Therefore, the
follow-up time to measure outcomes and harms should be
of sufficient length to cover critical periods of potential re-
lapses and withdrawal symptoms. For instance, in single
medication discontinuations, the minimal length of the
follow-up time may be guided with regard to the duration
of action of the medication to be stopped [41]. However,
usually time frames for benefits and harms are much longer
and can take weeks, months or years. For example, in de-
prescribing trials of antihypertensive medication, one may
measure a relevant increase in blood pressure after a few
weeks; however, more of concern is the hospitalizations
due to hypertensive crisis, myocardial infarction, and
stroke. In polypharmacy trials, the observed time frames
of restarts after discontinuation may be taken into account
[42,43]. Whatever rationale motivates the determination of
follow-up length, it should be reported to supportExample 9
In the trial to stop the use of diuretics in patients
who use it for ankle edema, the follow-up time was
explained as follows: "The length of the follow-up
period was chosen on the basis of literature in which
a rebound effect of diuretic withdrawal of 3 weeks
was mentioned. To work with a safe margin, we
choose a follow-up period of 6 weeks. Because the
first objective of our study was to investigate the ef-
fects of withdrawal, and not whether withdrawal
could be achieved for a substantial period of time, a
limited period was appropriate" [8].physicians in clinical management of their patients
(example 9) [8].3.5. CONSORT item 13bdflowchart
3.5.1. 13b: For each group, losses and exclusions after
randomization, together with reasons
The flow chart of the trial gives information on partici-
pation and refusal to participate or patient drop out. This in-
formation is highly relevant for the external validity.
Ideally, reasons for nonparticipation are known. In a de-
prescribing trial, reasons for dropping out of the trial are
of particular importance, as they might have to do with
withdrawal reactions or reoccurrence of symptoms [40].4. Discussion
We propose an elaboration of the CONSORT statement
for randomized controlled trials to enable more transpar-
ency in the reporting of deprescribing trials. Including
points relevant to prescribing/deprescribing trials in a
revised CONSORT statement would be a good way to facil-
itate this. As in all trials, in deprescribing trials all phases of
the protocol need to be thoroughly addressed both in design
development and reporting. Although design features for
deprescribing trials are often equally relevant for trials of
new drugs, owing to the nature of deprescribing trials, more
detail is required for a number of CONSORT items: trial
design, participants, intervention, outcomes and harms,
and the flowchart. Deprescribing trials are not new, but
the deprescribing perspective of rational and safe use of
medication has received more attention over the past few
years. Initiatives, such as ‘‘deprescribing.org’’ [44] and
the ‘‘Australian Deprescribing Network (AdeN)’’ [45], pro-
vide support for clinicians and researchers. These elabora-
tions are relevant both for readers of deprescribing trials
and researchers planning a deprescribing trial.
The CONSORT statement provides a checklist to guide
reporting of randomized trials to allow greater standardiza-
tion and transparency of the trial process for users of
research [46]. Most medical journals now require authors
of trials to submit the CONSORT checklist with their
article and these are often published with the trial. Similar
consensus statements for the reporting of other designs
have emerged, such as STROBE [47] for observational
studies and STARD [48] for diagnostic studies. Extensions
to CONSORT have been developed to cater for trials with a
specific design feature, such as cluster-randomized trials or
noninferiority and equivalence trials. Our group of experts
on deprescribing trials agreed that when deprescribing trials
use a conventional parallel group randomized trial design
all CONSORT items are applicable, but more detail is
needed only for specific items.
Specific design issues are directly related to the clinical
aim of deprescribing. In planning a deprescribing trial, the
94 J.W. Blom et al. / Journal of Clinical Epidemiology 127 (2020) 87e95implications for the hypothesis to be tested, the sample size,
and the type of analysis must be thoroughly thought through.
For example, because continuing a medication would be
more intrusive and more expensive than discontinuation, it
should be sufficient to demonstrate that discontinuation is
not clinically worse than continuation (i.e., that continuation
is not better). This means that a noninferiority design with
one-sided testing (and thereby a smaller sample size) would
suffice [27]. In addition, in contrast to usual (‘‘prescription’’)
drug trials, when the intervention is focused on discontinua-
tion of medication and the control condition is in fact contin-
uation of this medication [23], one could consider the role of
blinding. There is an essential difference between blinded
(purely pharmacological) discontinuation and open discon-
tinuation of the clinical act of prescribing medication, and
it is important to select the most appropriate option for the
clinical research question at stake.
A recent observational study of reporting in deprescribing
trials points to the variability of reporting and, more specif-
ically, the lack of detail about the intervention [49]. Suffi-
cient information about the interventions, including the
‘‘usual care’’ option, is important for clinical interpretation
of the results and replicability of the intervention in clinical
practice. Likewise, it is important that the results are reported
in more detail; for instance, who stopped completely or
partly (e.g., dose reduction), who restarted medication (and
for what reason), and who assessed the outcomes. Harms re-
porting should allow the estimation of incidence and severity
of any ADWRs and include whether or not ADWRs were ex-
pected and what was done to mitigate the impact of ADWRs
throughout the trial. As with any other intervention trial, a
prespecified protocol needs to be available and any planned
outcome measures have to be reported as well as the number
of and reasons for missing values.
This CONSORT elaboration for deprescribing trials is
based on a consensus building process. Experts in the field
of deprescribing from a wide range of countries and conti-
nents have contributed to this elaboration document. Howev-
er, as with all consensus processes, not all experts were
involved and some perspectives may have been missed.
However, this document is presented as a ‘‘work in progress’’
and as the suggested elaborations are being used and assessed
reporting guidance can be refined and improved.
Finally, taking the process of medication cessation and
deprescribing scientifically seriously should be accompa-
nied by better funding and regulation policies. Public and
private resources for funding deprescribing studies should
be substantially extended. Deprescribing studies are
currently scarce, which is in huge contrast with the growing
acknowledgment of polypharmacy and medication over-
load and its impact on patients and society [50]. The
research agenda is clearly biased as sponsors of trials study-
ing the effects of new medication are generally not inter-
ested in studying the effects of deprescribing that same
medication. In this context, it would help if public supervi-
sion and registration authorities require, as with all clinicaltrials, well-designed and -reported deprescribing studies as
a criterion for medication registration. Such requirements
would considerably increase the quality and safety of care.CRediT authorship contribution statement
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